Market Report, "Czech Republic Pharmaceuticals & Healthcare Report Q4 2012", Published
Proposed legislative amendments to healthcare and pharmaceutical policy are negative for pharmaceutical companies operating in the Czech Republic, though not as damaging as harsh price erosion mechanisms introduced in previous years. The government will continue with measures designed to tighten public expenditure across the board, while the challenging economic outlook will negatively affect the availability of private funding for medical products and services. Despite mediumterm concerns, after 2012 we expect more normal growth to resume. We believe the need for...
View full press release